Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05377034
Overview
This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab [study arm], versus SIRT-Y90 followed by placebo [control arm] in patients with locally advanced Hepatocellular Carcinoma (HCC).
Phase
Phase 2
Contacts
Professor Pierce CHOW, MD, PhD (Principal Investigator)
pierce.chow.k.h@singhealth.com.sg
+65 6436 8000
Qingguang HAN
han.qingguang@nccs.com.sg
+65 6576 7657
ClinicalTrials.gov
NCT05377034Drug / Compound
Help us improve your experience